Printed From:


DUPIXENT is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with Type 2 inflammation characterised by:1

  • raised blood eosinophils (EOS)
  • and/or raised fraction of exhaled nitric oxide (FeNO),
  • who are inadequately controlled with high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment

DUPIXENT is an injectable biologic that inhibits both IL-4 and IL-13 signalling1–3

DUPIXENT is a biologic immunomodulator that targets more than one biomarker, unlike other available biologics1–3

  • Biological therapies aim to alter the immunopathogenesis leading to asthma rather than manage the downstream airway inflammation3
  • Other available biologics target either IgE or IL-5 whereas, DUPIXENT targets IL-4 and IL-31–3

What type of severe asthma patient can benefit from DUPIXENT?

The following criteria need to be met by your severe asthma patients:1

  • Patients 12 years and older with severe asthma
  • Patients with Type 2 inflammation, characterised by raised blood EOS and/or raised FeNO
  • Patients whose asthma is inadequately controlled with high-dose ICS plus another medicinal product for maintenance treatment

Severe asthma patients require treatments that will address their Type 2 patient profile



Illustrative patient profiles. Not actual patients.


DUPIXENT can be administered via
a pre-filled pen or a syringe1

EOS, eosinophils; FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroid; IL, interleukin.


  1. Sanofi Genzyme. Dupixent Summary of Product Characteristics, September 2021.
  2. Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35–50.
  3. Krings JG, et al. J Allergy Clin Immunol Pract. 2019;7(5):1379–1392.
  4. Peters MC, et al. J Allergy Clin Immunol. 2014;133(2):388–394.
  5. Doran E, et al. Front Med. 2017;4:139.